Keyphrases
Bone Tissue
100%
Growth Factors
100%
Insulin-like
100%
Phase II Trial
100%
A1 Receptor
100%
Temsirolimus
100%
Soft Tissue Sarcoma
100%
Cixutumumab
100%
Receptor Expression
26%
Immunohistochemistry
20%
Bone Sarcoma
13%
Treatment Group
6%
Hyperglycemia
6%
Clinical Outcomes
6%
Progression-free Survival
6%
Adverse Events
6%
Anemia
6%
Mammalian Target of Rapamycin (mTOR)
6%
Phase II Study
6%
Cancer Center
6%
National Cancer Institute
6%
Thrombocytopenia
6%
Sarcoma
6%
Memorial Sloan-Kettering Cancer Center
6%
MTOR Inhibitor
6%
Hypophosphataemia
6%
Clinical Activity
6%
Lymphopenia
6%
Intention-to-treat Analysis
6%
Progression-free
6%
Treatment Refractory
6%
Confirmed Diagnosis
6%
Synergistic Antitumor Activity
6%
Flat Dose
6%
Oral mucositis
6%
Optimal Two-stage Design
6%
Medicine and Dentistry
Bone Tissue
100%
Temsirolimus
100%
Soft Tissue Sarcoma
100%
Cixutumumab
100%
Somatomedin C Receptor
100%
Receptor Expression
26%
Malignant Neoplasm
20%
Immunohistochemistry
20%
Arm
20%
Progression Free Survival
13%
Osteosarcoma
13%
Adverse Event
6%
Anemia
6%
Hyperglycemia
6%
Intention-to-Treat Analysis
6%
Antineoplastic Activity
6%
Thrombocytopenia
6%
Mammalian Target of Rapamycin Inhibitor
6%
Hypophosphatemia
6%
Mammalian Target of Rapamycin
6%
Lymphocytopenia
6%
Receptor Antibody
6%
Oral Mucositis
6%
Connective Tissue Cancer
6%
Treatment Group
6%